Publications by authors named "Andy Pike"

Claim this Profile
L
Lessons learned in linking PROTACs from discovery to the clinic.
Andy Pike, Esther C Y Lee, Iacovos N Michaelides, Markus Schade, Ankit Sharma

Nat Rev Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro ADME Profiling of PROTACs: Successes, Challenges, and Lessons Learned from Analysis of Clinical PROTACs from a Diverse Physicochemical Space.
Abhishek Srivastava, Andy Pike, Magda Swedrowska, Samuel Nash, Ken Grime

J Med Chem· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization toward orally available bifunctional protein degraders.
Giulia Apprato, Giulia Caron, Gauri Deshmukh, Diego Garcia-Jimenez, Robin Thomas Ulrich Haid, Andy Pike

Expert Opin Drug Discov· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}--methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor.
Jeffrey W Johannes, Amber Y S Balazs, Derek Barratt, Michal Bista, Matthew D Chuba, Andy Pike

J Med Chem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural and Physicochemical Features of Oral PROTACs.
Markus Schade, James S Scott, Thomas G Hayhow, Andy Pike, Ina Terstiege

J Med Chem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer.
Sharan K Bagal, Peter C Astles, Coura Diène, Argyrides Argyrou, Claire Crafter, Andy Pike

J Med Chem· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Intramolecular Reactions and Chemical Degradation in the Apparent Biotransformation Pathways of a Series of SYK Inhibitors.
Beatriz Calle, Bernard Barlaam, Coura Diène, Eva Lenz, Scott Martin, Andy Pike

Drug Metab Dispos· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.
Anna D Staniszewska, Domenic Pilger, Sonja J Gill, Kunzah Jamal, Natacha Bohin, Andy Pike

Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders.
Laurie P Volak, Heide Marika Duevel, Sara Humphreys, David Nettleton, Colin Phipps, Andy Pike

Drug Metab Dispos· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitors.
Neil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, Bernard Barlaam, Scott Boiko, Andy Pike

Bioorg Med Chem Lett· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper.
Giuditta Illuzzi, Anna D Staniszewska, Sonja J Gill, Andy Pike, Lisa McWilliams

Clin Cancer Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs).
Kevin Beaumont, Andy Pike, Michael Davies, Adriana Savoca, Christina Vasalou

Xenobiotica· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs.
Andy Pike, Barry Jones, Roshini Markandu, Daniel O'Neill

Drug Metab Dispos· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Method for Preventing Non-specific Binding in Equilibrium Dialysis Assays Using Solutol® as an Additive.
Abhishek Srivastava, Andy Pike, Beth Williamson, Katherine Fenner

J Pharm Sci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
Bernard Barlaam, Robert Casella, Justin Cidado, Calum Cook, Chris De Savi, Andy Pike, Kurt G Pike

J Med Chem· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors.
Bernard Barlaam, Scott Boiko, Scott Boyd, Hannah Dry, Lakshmaiah Gingipalli, Andy Pike

Bioorg Med Chem Lett· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective.
Andy Pike, Beth Williamson, Stephanie Harlfinger, Scott Martin, Dermot F McGinnity

Drug Discov Today· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a series of potent, selective and orally bioavailable SYK inhibitors.
Neil P Grimster, Lakshmaiah Gingipalli, Bernard Barlaam, Qibin Su, XiaoLan Zheng, Andy Pike

Bioorg Med Chem Lett· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.
Sameer P Kawatkar, Bernard Barlaam, Paul Kemmitt, Iain Simpson, David Watson, Andy Pike

Bioorg Med Chem Lett· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Identification of a Novel, Functionally Subtype Selective GABA Positive Allosteric Modulator (PF-06372865).
Robert M Owen, David Blakemore, Lishuang Cao, Neil Flanagan, Rebecca Fish, Andy Pike

J Med Chem· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of organic anion-transporting polypeptides and formulation in the clearance and distribution of a novel Na 1.7 channel blocker.
Andy Pike, Neil J Flanagan, R Ian Storer, Nigel A Swain, Elaine Tseng

Biopharm Drug Dispos· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABA receptor positive allosteric modulator PF-06372865.
Sarah A Nickolls, Rachel Gurrell, Guido van Amerongen, Juha Kammonen, Lishuang Cao, Andy Pike

Br J Pharmacol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly potent and selective Na1.7 inhibitors for use as intravenous agents and chemical probes.
R Ian Storer, Andy Pike, Nigel A Swain, Aristos J Alexandrou, Bruce M Bechle

Bioorg Med Chem Lett· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na1.7.
Nigel A Swain, Dave Batchelor, Serge Beaudoin, Bruce M Bechle, Paul A Bradley, Andy Pike

J Med Chem· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rat pharmacokinetics and pharmacodynamics of a sustained release formulation of the GABAA alpha5-selective compound L-655,708.
John R Atack, Andy Pike, Ashley Clarke, Susan M Cook, Bindi Sohal

Drug Metab Dispos· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis